Heparin antithrombotics

Description Results NMA

Topical liposomal heparin spraygel (4 puffs of 458 IU three times daily) (n=-9)

vs.

clexane (40 mg once daily) (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Topical liposomal heparin-spraygel (lipohep 2400 IU/g, 4 spray puffs three times daily) for 7-14 days (n=-9)

vs.

enoxaparin (40 mg s.c.) for 7-14 days (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

UFH (s.c. 12500 IU for one week then 10000 IU) for 4 weeks (n=-9)

vs.

UFH (5000 IU) (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Bleeding (early) ∞ [NaN; ∞]

Complete clot lysis (late) 1.25 [0.61; 2.56]

Post-thrombotic syndrome (late) 0.82 [0.56; 1.21]

Leg ulceration (late) 2.00 [0.20; 20.49]

Stroke/intracerebral bleeding (eraly) NaN [NaN; NaN]

extension or recurrence of VTE 0.10 [0.01; 0.75]

major hemorrhage 0.25 [0.03; 2.16]

extension or recurrence of VTE 3.73 [1.10; 12.68]

major hemorrhage 1.02 [0.15; 6.98]

major hemorrhage 2.04 [0.39; 10.65]

extension or recurrence of VTE 1.02 [0.31; 3.31]

extension or recurrence of VTE 0.15 [0.04; 0.65]

major hemorrhage 1.00 [0.15; 6.82]

major hemorrhage 1.92 [0.18; 20.43]

extension or recurrence of VTE 0.27 [0.06; 1.25]

major hemorrhage 0.54 [0.18; 1.56]

extension or recurrence of VTE 1.93 [0.36; 10.35]

tPA 20 mg IV into pedal vein over 4 hours each day for 7 days. Heparin IV given concomitantly, with adjustment (n=-9)

vs.

heparin IV, adjusted for 7 days (n=-9)

single blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

heparin and phenprocoumon for 3 months (n=48)

vs.

phenylbutazone (n=42)

open

Sample size: 48/42

Primary endpoint:

FU duration:

subcutaneous sodic heparin 30 000 U daily (mean) (n=23)

vs.

intravenous sodic heparin 30 000 U daily (mean) (n=25)

Sample size: 23/25

Primary endpoint:

FU duration:

subcutaneous calcic heparin 37 000 U daily (mean) (n=50)

vs.

intravenous sodic heparin 36 800 U daily (mean) (n=50)

Sample size: 50/50

Primary endpoint:

FU duration:

subcutaneous sodic heparin 36 800 U daily (mean) (n=72)

vs.

intravenous sodic heparin 33 250 U daily (mean) (n=69)

Sample size: 72/69

Primary endpoint:

FU duration:

subcutaneous sodic heparin 32 300 U daily (mean) (n=57)

vs.

intravenous sodic heparin 29 700 U daily (mean) (n=58)

Sample size: 57/58

Primary endpoint:

FU duration:

subcutaneous calcic heparin 29 200 U daily (mean) (n=51)

vs.

intravenous calcic heparin 29 600 U daily (mean) (n=52)

Sample size: 51/52

Primary endpoint:

FU duration:

subcutaneous calcic heparin 29 375 U daily (mean) (n=50)

vs.

intravenous calcic heparin 24 384 U daily (mean) (n=50)

Sample size: 50/50

Primary endpoint:

FU duration:

subcutaneous sodic heparin 34 400 U daily (mean) (n=48)

vs.

intravenous sodic heparin 37 000 U daily (mean) (n=46)

Sample size: 48/46

Primary endpoint:

FU duration:

subcutaneous calcic heparin 33 800 U daily (mean) (n=138)

vs.

intravenous sodic heparin 31 700 U daily (mean) (n=133)

Sample size: 138/133

Primary endpoint:

FU duration:

Fatal PE 1.09 [0.08; 15.42]

anticoagulants (s.c. heparin followed by oral warfarin) (duration NA) (n=11)

vs.

s.c. saline followed by oral placebo tablets (n=12)

double blind

Sample size: 11/12

Primary endpoint:

FU duration: